Neuronoff Demonstrates Multi-Site IPG Compatibility for Injectrode® Platform

Needle-Delivered Tripolar Electrode Connects to Standard IPG Connectors; Selectively Stimulates Lumbar DRG, Peripheral Nerve, and Sacral Targets from Single Implantable Pulse Generator

Mar. 16, 2026 at 12:57pm

Got story updates? Submit your updates here. ›

Neuronoff, Inc., a clinical-stage neuromodulation company, announced successful chronic large animal demonstration of its IPG-compatible Injectrode® platform, in which a single remotely controlled Implantable Pulse Generator (IPG) independently stimulated three anatomically distinct neural targets via standard Bal Seal connectors.

Why it matters

The significance of this demonstration is that the IPG-Injectrode is delivered entirely through a ~1.5mm needle and connects to IPGs via industry-standard Bal Seal connectors, allowing any IPG manufacturer to address peripheral nerve stimulation (PNS) targets as well as the DRG, sacral nerves, lumbar dorsal rami, ganglia on the sympathetic chain, and beyond — that have historically required open surgical approaches or remained outside the reach of implantable systems in clinical practice.

The details

Multi-contact Injectrodes were placed at the Lumbar Dorsal Root Ganglion (DRG), the Lumbar Dorsal Ramus, and the Sacral S2 foramen — sites routinely accessed by interventional pain physicians today using needle-based diagnostic blocks, or traditional neuromodulation implants requiring surgery to implant. Each target was stimulated selectively and independently from a single IPG, demonstrating the platform's current steering and multi-channel capabilities.

  • The Injectrode platform is designed to align with established CPT reimbursement codes 64555 and 64590, covering peripheral nerve stimulation trial, treatment and implant procedures.
  • Neuronoff's near-term focus remains the 510(k) submission of its externally powered Injectrode PNS system, targeting FDA submission in mid 2026.

The players

Neuronoff, Inc.

A clinical-stage neuromodulation company developing the Injectrode®, a minimally invasive peripheral nerve stimulation platform that delivers neuromodulation therapy through a standard clinical needle.

Manfred Franke

The CEO of Neuronoff.

Got photos? Submit your photos here. ›

What they’re saying

“Spinal cord stimulation (SCS) has been the primary market for IPGs for decades, but the vast majority of treatable nerve targets with easy access are peripheral. The IPG-Injectrode removes the surgical barrier in PNS, enables novel multi-contact approaches for DRG and SCS, and expands the reach of any IPG platform into indications that weren't previously accessible. Any IPG can now reach any nerve a physician can access with a needle — and that is a fundamentally different addressable market.”

— Manfred Franke, CEO of Neuronoff (rivertonjournal.com)

“Our external EPG system and IPG-compatible system are designed as a continuum. The patient journey begins with a minimally invasive step not unlike a steroid injection or needle-based RF ablation — no suturing, no scarring, fully compatible with clinic workflows. Conversion to IPG-based chronic therapy is a natural next step, and we've built the platform so that step requires no changes to existing IPG hardware and no new reimbursement codes, and significantly reduces procedural time compared to current surgical approaches.”

— Manfred Franke, CEO of Neuronoff (rivertonjournal.com)

What’s next

Neuronoff's near-term focus remains the 510(k) submission of its externally powered Injectrode PNS system, targeting FDA submission in mid 2026.

The takeaway

The IPG-Injectrode platform removes the surgical barrier for peripheral nerve stimulation (PNS) and expands the reach of any IPG platform into indications that weren't previously accessible, allowing any IPG to reach any nerve a physician can access with a needle.